Abstract
Examples of pharmaco-imaging in translational science and research include whole body infrared imaging of normal healthy mouse, magnetic resonance imaging of normal healthy mouse calf muscle, and magnetic resonance imaging of relapsing-remitting multiple sclerosis patient brain. Rationales, experimental design, study outcomes, and conclusions are presented.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alter A, Duddy M, Hebert S et al (2003) Determinants of human B cell migration across brain endothelial cells. J Immunol 170(9):4497–4505
Augusto V, Padovani CR, Campos GER (2004) Skeletal muscle types in C57BL/J mice. Braz J Morphol Sci 21(2):89–94
Bleeker WK, Munk ME, Mackus WJM et al (2007) Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 140:303–312
Cook SD (2006) Evidence for an infectious etiology of multiple sclerosis. In: Cook SD (ed) Handbook of multiple sclerosis, 4th edn. Taylor & Francis, New York
Gibiansky L et al (2008) Approximations of the target-mediated drug disposition and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573–591
Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
Kuenz B, Lutterotti A, Ehling R et al (2008) Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 3(7):e2559
Macallan DC, Wallace D, Zhang Y et al (2004) Rapid turnover of effector memory CD4+ T cells in healthy humans. J Exp Med 200(2):255–260
Mager DE, Woo S, Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies in humans. Drug Met Pharmacokinet 24(1):16–24
Petereit HF, Rubbert-Roth A (2009) Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 15(2):189–192
Savage VM et al (2004) The predominance of quarter-power allometric scaling in biology. Funct Ecolo 18(2):257–282
Sharma A, Jusko W (1998) Characteristics of indirect pharmacodynamics models and applications to clinical drug responses. Br J Clin Pharmacol 45(3):229–239
Sorensen PS, Drulovic J, Havrdova E (2010) Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS)—24-week results of a phase II study. In 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct 13–16, 2010 , Gothenburg: SE
Sormani MP, Bruzzi P, Rovaris M et al (2001) Modelling new enhancing MRI lesion counts in multiple sclerosis. Mult Scler 7:298–304
Tourtellotte WW (1975) What is multiple sclerosis? Laboratory criteria for diagnosis. In: Davison AN, Humphrey JH, Liversedge AL et al (eds) Multiple sclerosis research, HMSO, London, p 9
West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276(5309):122–126
Acknowledgments
The ADAM TS 5 PK study was designed by a GlaxoSmithKline(GSK) team including Elefante, L.; Freedman, I.; Larkin, J.; Liu, F.; Lohr, T.; Matheny, C.; and White, J.
The anti-myostatin PK/PD study “memma2” was designed by a GSK team including Ashman, S.; Chagani, K.; Freedman, I.; and Reid, J.
The OMS112831 study was designed by a GSK team including Bhangu, S.; Carranza, J.; Derosier, F.; Depew, C.; Edwards, T.; Freedman, I.; Grove, R.; Hall, A.; Herrera, P.; Hill-Zabala, C.; Lopez, M.; Nichols, L.; Rogers, R.; Schifano, L.; Schindielorz, A.; Sue-Ling, K.; Tolson, J.; and Watson, D.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Freedman, I. (2014). Pharmaco-Imaging in Translational Science and Research. In: Moyer, B., Cheruvu, N., Hu, TC. (eds) Pharmaco-Imaging in Drug and Biologics Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 8. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8247-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8247-5_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8246-8
Online ISBN: 978-1-4614-8247-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)